Abstract
September 2014, the period covered by this article, was characterized by continued prospective and actual acquisition activity and some big possible deals such as Valeant and Allergan, were still in prospect. A number of drug approvals for medicines with novel therapeutic targets such as anti-PD-1 for oncology or employing delivery technologies such as corticosteroid intravitreal implants for diabetic macular edema were announced during the month.
Financial & competing interests disclosure
The author is a salaried employee of Bristol-Myers Squibb, which has active research programs and marketed medicines in some of the therapeutic areas mentioned in this article. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.